Clinical and Molecular Hepatology (Clin Mol Hepatol, CMH)

Letter to the Editor

Letter regarding “Is liver biopsy essential to identifying the immune tolerant phase of chronic hepatitis B?”

Halil Haldun Emiroglu

Clin Mol Hepatol. 2023;29(3):812-812. Published online May 8, 2023

DOI: https://doi.org/10.3350/cmh.2023.0132

View: 823 Download: 15

Review

Development of hepatocellular carcinoma in treated and untreated patients with chronic hepatitis B virus infection

Chih-Lin Lin, Jia-Horng Kao

Clin Mol Hepatol. 2023;29(3):605-622. Published online February 15, 2023

DOI: https://doi.org/10.3350/cmh.2022.0342

View: 2065 Download: 226 Citations: 3

Correspondence

Correspondence on Letter regarding “Long-term prognosis and the need for histologic assessment of chronic hepatitis B in the serological immune tolerant phase”

Jeong-Ju Yoo, Sang Gyune Kim

Clin Mol Hepatol. 2023;29(2):513-515. Published online February 15, 2023

DOI: https://doi.org/10.3350/cmh.2023.0044

View: 1237 Download: 34

Letter to the Editor

Letter regarding “Long-term prognosis and the need for histologic assessment of chronic hepatitis B in the serological immune-tolerant phase”

Chia-Ming Chu, Yun-Fan Liaw

Clin Mol Hepatol. 2023;29(2):510-512. Published online January 30, 2023

DOI: https://doi.org/10.3350/cmh.2023.0018

View: 1347 Download: 49 Citation: 1

Review

The role of different viral biomarkers on the management of chronic hepatitis B

Lung-Yi Mak, Rex Wan-Hin Hui, James Fung, Wai Kay Seto, Man-Fung Yuen

Clin Mol Hepatol. 2023;29(2):263-276. Published online January 19, 2023

DOI: https://doi.org/10.3350/cmh.2022.0448

View: 2744 Download: 233 Citation: 1

Overview of Asian clinical practice guidelines for the management of hepatocellular carcinoma: An Asian perspective comparison

Yuri Cho, Bo Hyun Kim, Joong-Won Park

Clin Mol Hepatol. 2023;29(2):252-262. Published online March 10, 2023

DOI: https://doi.org/10.3350/cmh.2023.0099

View: 2456 Download: 184 Citation: 1

Original Article

Hepatitis B virus pre-genomic RNA and hepatitis B core-related antigen reductions at week 4 predict favourable hepatitis B surface antigen response upon long-term nucleos(t)ide analogue in chronic hepatitis B

Lung-Yi Mak, Danny Wong, Alison Kuchta, Martina Hilfiker, Aaron Hamilton, Ning Chow, XianHua Mao, Wai Kay Seto, Man-Fung Yuen

Clin Mol Hepatol. 2023;29(1):146-162. Published online August 19, 2022

DOI: https://doi.org/10.3350/cmh.2022.0172

View: 3542 Download: 197 Citations: 7

COVID-19 vaccine immunogenicity among chronic liver disease patients and liver transplant recipients: A meta-analysis

Ka Shing Cheung, Chiu Hang Mok, Xianhua Mao, Ruiqi Zhang, Ivan FN Hung, Wai Kay Seto, Man Fung Yuen

Clin Mol Hepatol. 2022;28(4):890-911. Published online June 3, 2022

DOI: https://doi.org/10.3350/cmh.2022.0087

View: 3786 Download: 167 Citations: 18

Review

The best predictive model for hepatocellular carcinoma in patients with chronic hepatitis B infection

Jung Hwan Yu, Soon Gu Cho, Young-Joo Jin, Jin-Woo Lee

Clin Mol Hepatol. 2022;28(3):351-361. Published online November 26, 2021

DOI: https://doi.org/10.3350/cmh.2021.0281

View: 3801 Download: 216 Citations: 12

Guideline

KASL clinical practice guidelines for management of chronic hepatitis B

Clin Mol Hepatol. 2022;28(2):276-331. Published online April 1, 2022

DOI: https://doi.org/10.3350/cmh.2022.0084 Correction in: Clin Mol Hepatol 2022;28(4):940

View: 8406 Download: 511 Citations: 26

Original Article

Tenofovir alafenamide treatment may not worsen the lipid profile of chronic hepatitis B patients: A propensity score-matched analysis

Joonho Jeong, Jung Woo Shin, Seok Won Jung, Eun Ji Park, Neung Hwa Park

Clin Mol Hepatol. 2022;28(2):254-264. Published online December 28, 2021

DOI: https://doi.org/10.3350/cmh.2021.0314

View: 3777 Download: 255 Citations: 11

Editorial

Is tenofovir and entecavir combination therapy still the optimal treatment for chronic hepatitis B patients with prior suboptimal response?

Byoung Kuk Jang

Clin Mol Hepatol. 2020;26(3):312-314. Published online July 1, 2020

DOI: https://doi.org/10.3350/cmh.2020.0099

View: 4286 Download: 109 Citation: 1

Review

KASL clinical practice guidelines for management of chronic hepatitis B

Clin Mol Hepatol. 2019;25(2):93-159. Published online June 12, 2019

DOI: https://doi.org/10.3350/cmh.2019.1002

View: 22583 Download: 623 Citations: 134

Case Report

Favorable effect of corticosteroids in treating acute-on-chronic liver failure underlying chronic hepatitis B

Hyeji Kim, Jung Hyun Kwon, Yong Hee Kim, Soon Woo Nam, Jong Yul Lee, Jeong Won Jang

Clin Mol Hepatol. 2018;24(4):430-435. Published online November 27, 2017

DOI: https://doi.org/10.3350/cmh.2017.0016

View: 7431 Download: 221 Citations: 2

Original Article

Characterization and evaluation of liver fibrosis grade in patients with chronic hepatitis B virus infection and normal transaminases

San Juan López Cristina, Casado Martín Marta, González Sánchez Mercedes, Porcel Martín Almudena, Hernández Martínez Álvaro, Vega Sáenz Jose Luis, Parrón Carreño Tesifón

Clin Mol Hepatol. 2018;24(4):384-391. Published online July 4, 2018

DOI: https://doi.org/10.3350/cmh.2018.0004

View: 7130 Download: 193 Citations: 9

Review

Management of chronic hepatitis B patients in immunetolerant phase: what latest guidelines recommend

Grace Lai-Hung Wong

Clin Mol Hepatol. 2018;24(2):108-113. Published online January 22, 2018

DOI: https://doi.org/10.3350/cmh.2017.0068

View: 11894 Download: 501 Citations: 35

Editorial

Is it possible to predict the development of an entecavir resistance mutation in patients with chronic hepatitis B in clinical practice?

Joon Yeul Nam, Jeong-Hoon Lee

Clin Mol Hepatol. 2017;23(4):311-313. Published online December 4, 2017

DOI: https://doi.org/10.3350/cmh.2017.0069

View: 5514 Download: 139

Original Article

Efficacy of tenofovir-based rescue therapy for chronic hepatitis B patients with resistance to lamivudine and entecavir

Hee-Jeong Jeon, Seok Won Jung, Neung Hwa Park, Yujin Yang, Jin-Hee Noh, Jae-Sung Ahn, Hyung Rae Kim, Jae Ho Lee, Jung Woo Shin

Clin Mol Hepatol. 2017;23(3):230-238. Published online June 30, 2017

DOI: https://doi.org/10.3350/cmh.2017.0003

View: 8793 Download: 160 Citations: 13

Editorial

Is tenofovir monotherapy a sufficient defense line against multi-drug resistant hepatitis B virus?

Yun Bin Lee, Jeong-Hoon Lee

Clin Mol Hepatol. 2017;23(3):219-221. Published online September 19, 2017

DOI: https://doi.org/10.3350/cmh.2017.0045

View: 7149 Download: 150 Citations: 2

Original Article

Risk score model for the development of hepatocellular carcinoma in treatment-naïve patients receiving oral antiviral treatment for chronic hepatitis B

Won Sohn, Ju-Yeon Cho, Ji Hoon Kim, Jung Il Lee, Hyung Joon Kim, Min-Ah Woo, Sin-Ho Jung, Yong-Han Paik

Clin Mol Hepatol. 2017;23(2):170-178. Published online May 16, 2017

DOI: https://doi.org/10.3350/cmh.2016.0086

View: 8741 Download: 210 Citations: 41

Clinical impact of the early alanine amininotransferase flare during tenofovir monotherapy in treatment-naïve patients with chronic hepatitis B

Hee Yeon Seo, Han Ah Lee, Soon Young Ko, Joon Ho Wang, Jeong Han Kim, Won Hyeok Choe, So Young Kwon

Clin Mol Hepatol. 2017;23(2):154-159. Published online May 8, 2017

DOI: https://doi.org/10.3350/cmh.2016.0067

View: 6887 Download: 170 Citations: 7

Preemptive antiviral therapy with entecavir can reduce acute deterioration of hepatic function following transarterial chemoembolization

Sun Hong Yoo, Jeong Won Jang, Jung Hyun Kwon, Seung Min Jung, Bohyun Jang, Jong Young Choi

Clin Mol Hepatol. 2016;22(4):458-465. Published online December 25, 2016

DOI: https://doi.org/10.3350/cmh.2016.0054

View: 8225 Download: 129 Citations: 7

Efficacy of switching from adefovir to tenofovir in chronic hepatitis B patients who exhibit suboptimal responses to adefovir-based combination rescue therapy due to resistance to nucleoside analogues (SATIS study)

Hye Won Lee, Jun Yong Park, Beom Kyung Kim, Moon Young Kim, Jung Il Lee, Young Suk Kim, Ki Tae Yoon, Kwang-Hyub Han, Sang Hoon Ahn

Clin Mol Hepatol. 2016;22(4):443-449. Published online November 25, 2016

DOI: https://doi.org/10.3350/cmh.2016.0037

View: 9187 Download: 157 Citations: 7

Editorial

Switch to tenofovir-based therapy or to continue adefovir-based therapy in CHB patients with suboptimal response to adefovir-based combination?

Byung-Cheol Song

Clin Mol Hepatol. 2016;22(4):439-442. Published online December 25, 2016

DOI: https://doi.org/10.3350/cmh.2016.0108

View: 7028 Download: 110

Review

New perspectives of biomarkers for the management of chronic hepatitis B

Chih-Lin Lin, Jia-Horng Kao

Clin Mol Hepatol. 2016;22(4):423-431. Published online December 25, 2016

DOI: https://doi.org/10.3350/cmh.2016.0069

View: 12119 Download: 533 Citations: 43

Original Article

Comparison of the clinical outcomes between antiviral-naïve patients treated with entecavir and lamivudine-resistant patients receiving adefovir add-on lamivudine combination treatment

Hong Joo Kim, Soo Kyung Park, Hyo Joon Yang, Yoon Suk Jung, Jung Ho Park, Dong Il Park, Yong Kyun Cho, Chong Il Sohn, Woo Kyu Jeon, Byung Ik Kim, Kyu Yong Choi

Clin Mol Hepatol. 2016;22(3):350-358. Published online September 25, 2016

DOI: https://doi.org/10.3350/cmh.2016.0019

View: 8374 Download: 136 Citation: 1

Obesity and hepatocellular carcinoma in patients receiving entecavir for chronic hepatitis B

Jaemin Lee, Sun Hong Yoo, Won Sohn, Hyung Woo Kim, Yong Sun Choi, Jung Ho Won, Jin Young Heo, Sang Jong Park, Young Min Park

Clin Mol Hepatol. 2016;22(3):339-349. Published online September 25, 2016

DOI: https://doi.org/10.3350/cmh.2016.0021

View: 10896 Download: 157 Citations: 19

Editorial

Does obesity increase the risk of hepatocellular carcinoma in chronic hepatitis B patients?

Byoung Kuk Jang

Clin Mol Hepatol. 2016;22(3):336-338. Published online September 25, 2016

DOI: https://doi.org/10.3350/cmh.2016.0104

View: 7367 Download: 113 Citation: 1

Case Report

Tenofovir-associated nephrotoxicity in patients with chronic hepatitis B: two cases

Hyeki Cho, Yuri Cho, Eun Ju Cho, Jeong-Hoon Lee, Su Jong Yu, Kook-Hwan Oh, Kyoungbun Lee, Syifa Mustika, Jung-Hwan Yoon, Yoon Jun Kim

Clin Mol Hepatol. 2016;22(2):286-291. Published online June 25, 2016

DOI: https://doi.org/10.3350/cmh.2015.0066

View: 9444 Download: 170 Citations: 13

Original Article

The efficacy of tenofovir-based therapy in patients showing suboptimal response to entecavir-adefovir combination therapy

Jeong Han Kim, Sung Hyun Ahn, Soon Young Ko, Won Hyeok Choe, Kyun-Hwan Kim, So Young Kwon

Clin Mol Hepatol. 2016;22(2):241-249. Published online June 15, 2016

DOI: https://doi.org/10.3350/cmh.2015.0053

View: 9213 Download: 136 Citations: 4

1 | 2 | 3 |

Viewed By 7179	Assessing the performance of ChatGPT in answering questions regarding cirrhosis and hepatocellular carcinoma
Viewed By 6208	A decade of liver organoids: Advances in disease modeling
Viewed By 4029	Hepatitis B core-related antigen: A novel and promising surrogate biomarker to guide anti-hepatitis B virus therapy
Viewed By 3385	MAFLD: How is it different from NAFLD?
Viewed By 3030	Hepatorenal syndrome: Current concepts and future perspectives

Cited By 117	KASL clinical practice guidelines: Management of nonalcoholic fatty liver disease
Cited By 54	2022 KLCA-NCC Korea practice guidelines for the management of hepatocellular carcinoma
Cited By 52	From nonalcoholic fatty liver disease to metabolic-associated fatty liver disease: Big wave or ripple?
Cited By 46	Obesity and the risk of primary liver cancer: A systematic review and meta-analysis
Cited By 46	Lactobacillus attenuates progression of nonalcoholic fatty liver disease by lowering cholesterol and steatosis

Search